Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global ...

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price ... month, there's been a 1.34% fall in the Zacks Consensus EPS estimate. Eli Lilly ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

I think Eli Lilly and Company's stock correction may be ending ... what the current consensus anticipates (based on historical tendency), the price target for LLY arrives at $945.42.

ByInvesting.com • Aug 27, 2024 Eli Lilly stock maintains In Line rating, new vial forms match net prices Evercore ISI has maintained an In Line rating on shares of pharmaceutical giant Eli Lilly ...